Aspire BioPharma is trading 5.55% up at $8.63, with no specific catalyst identified. - The latest reported company development was a September 29 change of independent auditor, with CBIZ CPAs replacing Turner Stone. - The filing reported no disagreements with the former auditor, but noted previously disclosed material weaknesses and substantial doubt about the company’s ability to continue as a going concern. - Market indices were mixed, with none moving more than 0.5% in the same direction. No trading-volume figure was provided, and available reporting does not link the auditor change to the share-price move.